Search





Search





Markets
/
Stocks
/
ikt
/

Inhibikase Therapeutics Inc

IKT

Add to Watchlist

2.330USD

+0.160+7.37%

Close 07-23 16:00（ET）Quotes delayed by 15 min

307.64MMarket Cap

LossP/E TTM

Inhibikase Therapeutics Inc

2.330

+0.160+7.37%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

IKT Cash Flow Statement

You can access the annual and quarterly cash flow statements of Inhibikase Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2020Q3

FY2020Q2

FY2020Q1

FY2019Q4

FY2019Q3

FY2019Q2

FY2019Q1

FY2018Q4

FY2018Q1

FY2017Q4

FY2017Q1

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-193.89%-12.06M

-40.60%-7.52M

-117.02%-10.59M

-10.29%-5.57M

-6.12%-4.10M

-55.28%-5.35M

-18.90%-4.88M

-10.71%-5.05M

35.25%-3.87M

3.20%-3.44M

25.43%-4.11M

-4.81%-4.57M

-51.80%-5.97M

13.17%-3.56M

-172.44%-5.50M

-2.57%-4.36M

0.00%-3.93M

-332.72%-4.10M

-2775.62%-2.02M

-39702.38%-4.25M

-1440.22%-3.93M

-14952.16%-946.53K

1210.35%75.52K

78.29%-10.67K

11.53%-255.43K

-99.37%6.37K

---6.80K

---49.14K

-551.46%-288.72K

4342.67%1.01M

-32.04%63.95K

---23.88K

--94.10K

Net income from continuing operations

-19.75%-16.38M

-4.96%-12.73M

-106.48%-11.93M

-99.93%-9.92M

-194.19%-13.68M

-190.40%-12.13M

-25.74%-5.78M

14.16%-4.96M

-3.84%-4.65M

2.36%-4.18M

-2.24%-4.60M

-24.53%-5.78M

3.51%-4.48M

15.13%-4.28M

-0.52%-4.49M

-76.01%-4.64M

-75.98%-4.64M

-317.36%-5.04M

-566.75%-4.47M

-524.88%-2.64M

-381.71%-2.64M

-180.92%-1.21M

44.69%-670.60K

82.00%-421.87K

68.47%-547.44K

66.00%-430.01K

---1.21M

---2.34M

-1289.25%-1.74M

-2933.61%-1.26M

32.68%-124.98K

--44.63K

---185.65K

Operating gains losses

-100.00%0.00

260.64%23.69K

267.76%24.16K

92.66%12.65K

-0.02%6.57K

-0.23%6.57K

-95.87%6.57K

30.24%6.57K

30.27%6.57K

291.61%6.58K

--159.20K

--5.04K

--1.68K

----

Other non-cash items

-119.19%-1.19M

--275.70K

---1.12M

---358.42K

--6.19M

-100.00%0.00

----

168.48%14.26K

-16.99%17.28K

--0.00

-100.00%0.00

-169.77%-20.82K

-88.55%20.82K

-100.00%0.00

-75.24%67.00K

-96.96%29.84K

-33.64%181.76K

88.49%239.41K

18.43%270.61K

689.46%980.06K

115.65%273.91K

-92.86%127.01K

-20.35%228.49K

-80.43%124.14K

--127.01K

--1.78M

--286.89K

--634.27K

-100.00%0.00

--0.00

--46.12K

Change in working capital

-103.79%-50.37K

136.28%409.20K

-381.54%-2.09M

453.56%466.81K

83.77%1.33M

-290.40%-1.13M

120.64%742.37K

-114.22%-132.03K

144.53%722.62K

-7.15%592.44K

129.66%336.46K

513.42%928.53K

-414.36%-1.62M

-1.85%638.09K

-159.19%-1.13M

106.97%151.37K

123.91%516.18K

174.47%650.11K

476.50%1.92M

-1604.05%-2.17M

-2731.58%-2.16M

-607.92%-873.02K

60.93%332.44K

-66.07%144.43K

-109.21%-76.24K

-88.70%171.88K

--206.58K

--425.72K

3538.74%827.60K

1283.16%1.52M

-85.74%22.74K

---128.53K

--159.53K

-Change in receivables

----

--0.00

-100.00%0.00

100.00%0.00

1191.93%79.60K

-136.41%-15.08K

-139.63%-24.64K

-124.26%-26.04K

-101.98%-7.29K

116.32%41.42K

118.68%62.16K

--107.34K

--369.10K

---253.81K

---332.77K

-100.00%0.00

162.01%31.32K

--248.17K

--35.67K

370.50%157.77K

-24.80%-50.52K

142.36%33.53K

---40.48K

---79.16K

-Change in prepaid expenses

-152.53%-462.36K

11.99%-516.02K

-601.00%-821.92K

349.01%133.07K

-7778.27%-183.09K

-309.06%-586.30K

-34.39%164.05K

-106.10%-53.44K

99.59%-2.32K

78.32%280.45K

-14.42%250.05K

541297.53%876.74K

-368.16%-564.82K

119.56%157.28K

-70.40%292.19K

99.99%-162.00

-146.00%-120.65K

-1854.62%-803.96K

11042.17%986.97K

-14015.75%-1.23M

8518.57%262.26K

-345.48%-41.13K

110.30%8.86K

-196.81%-8.68K

-99.20%3.04K

97.58%-9.23K

--4.21K

--8.97K

--378.21K

---382.08K

-100.00%0.00

--0.00

--625.00

-Change in other current assets

-285.34%-60.64K

-217.49%-37.21K

13.90%34.92K

13.82%33.80K

13.73%32.72K

13.66%31.67K

13.54%30.66K

13.48%29.70K

13.35%28.77K

-26.78%27.86K

--27.00K

--26.17K

--25.38K

--38.05K

----

-Change in other current liabilities

----

100.00%0.00

----

---23.68K

100.00%-1.00

102.14%23.68K

100.00%0.00

-100.00%0.00

-131.95%-142.62K

-2833.82%-1.11M

-2601.38%-1.07M

-54.91%367.19K

-18.01%446.41K

--40.56K

122.31%42.95K

223.65%814.30K

--544.50K

--0.00

-198.39%-192.53K

333.07%251.60K

152.84%195.68K

---107.95K

--77.39K

Cash from non-recurring investing activities

Cash from operating activities

-193.89%-12.06M

-40.60%-7.52M

-117.02%-10.59M

-10.29%-5.57M

-6.12%-4.10M

-55.28%-5.35M

-18.90%-4.88M

-10.71%-5.05M

35.25%-3.87M

3.20%-3.44M

25.43%-4.11M

-4.81%-4.57M

-51.80%-5.97M

13.17%-3.56M

-172.44%-5.50M

-2.57%-4.36M

0.00%-3.93M

-332.72%-4.10M

-2775.62%-2.02M

-39702.38%-4.25M

-1440.22%-3.93M

-14952.16%-946.53K

1210.35%75.52K

78.29%-10.67K

11.53%-255.43K

-99.37%6.37K

---6.80K

---49.14K

-551.46%-288.72K

4342.67%1.01M

-32.04%63.95K

---23.88K

--94.10K

Investing cash flow

Net cash from continuing investing activities

-100.00%0.00

--0.00

--452.02K

--0.00

----

--0.00

-100.00%0.00

----

--0.00

--200.17K

--43.09K

----

Capital expenditures

-100.00%0.00

--0.00

--452.02K

--0.00

----

--0.00

-100.00%0.00

----

--0.00

--200.17K

--43.09K

----

Net cash flow from disposal of fixed assets

-100.00%0.00

--0.00

--13.40K

--0.00

----

--0.00

-100.00%0.00

----

--0.00

--200.17K

--43.09K

----

Net cash flow from intangible asset transactions

-100.00%0.00

--0.00

--438.62K

----

Net cash flow from investment products

-474.24%-80.48M

99.74%-98.85K

-1237.96%-28.75M

287.06%9.84M

749.38%21.51M

-1732.19%-38.76M

-85.19%2.53M

--2.54M

43.28%-3.31M

-142.63%-2.12M

182.32%17.06M

----

---5.84M

--4.96M

---20.73M

----

Net cash flow from other investing activities

--0.00

----

--87.10K

----

Cash from non-current investing activities

Net cash flow from investing activities

-482.27%-80.48M

99.74%-98.85K

-1237.96%-28.75M

287.06%9.84M

735.73%21.05M

-1732.19%-38.76M

-85.19%2.53M

-0.26%2.54M

43.28%-3.31M

-142.63%-2.12M

181.53%17.06M

6017.70%2.55M

---5.84M

--4.96M

---20.93M

---43.09K

----

--87.10K

----

Financing cash flow

Cash flow from continuous financing activities

--2.90M

8.91%108.57M

-173.72%-134.13K

-99.02%31.77K

-100.00%0.00

72280.72%99.68M

259834.29%181.95K

9115.33%3.24M

-95.72%367.00K

---138.10K

--70.00

---35.99K

4289.61%8.58M

--0.00

-100.00%0.00

50.02%-204.77K

-100.00%0.00

144.53%29.89K

781091.20%41.47M

-263.79%-409.66K

1488387200.00%14.88M

---67.13K

531000.00%5.31K

1196.54%250.12K

100.00%1.00

--0.00

---1.00

-47.74%-22.81K

-33571.35%-1.41M

-53.70%-15.44K

--4.22K

---10.04K

Net cash flow from debt Issuance/repayment

----

--0.00

100.00%0.00

--0.00

-100.00%0.00

39.24%-248.91K

--0.00

1232.59%367.13K

-267.04%-409.66K

--0.00

2755100.00%27.55K

1175.19%245.25K

----

--0.00

---1.00

-47.74%-22.81K

99.89%-11.00

-490.37%-15.44K

---9.78K

--3.96K

Net cash flow from common stock issuance/repurchase

--2.90M

7.96%107.62M

-100.00%0.00

-100.00%150.00

-100.00%0.00

22053983.85%99.68M

259834.29%181.95K

9030.27%3.21M

-95.37%397.61K

--452.00

--70.00

---35.99K

--8.58M

--0.00

----

--0.00

----

--41.15M

-100.00%0.00

--0.00

--4.87K

--0.00

----

Proceeds from stock option exercised by employees

----

--562.91K

--250.93K

--31.62K

----

--0.00

-100.00%0.00

--0.00

-100.00%0.00

--44.14K

-100.00%0.00

--44.14K

--34.36K

----

--14.79M

----

Net cash flow from other financing activities

--0.00

--385.06K

---385.06K

----

100.00%0.00

----

--30.61K

---30.61K

---138.56K

----

--0.00

100.00%0.00

----

-100.00%0.00

78.77%-14.25K

-249.14%-77.65K

----

9713100.00%97.13K

---67.13K

---22.24K

----

100.00%1.00

--0.00

-10181.97%-1.41M

100.00%0.00

--14.00K

---14.00K

Net cash from non-recurrent financing activities

Net cash from financing activities

--2.90M

8.91%108.57M

-173.72%-134.13K

-99.02%31.77K

-100.00%0.00

72280.72%99.68M

259834.29%181.95K

9115.33%3.24M

-95.72%367.00K

---138.10K

--70.00

---35.99K

4289.61%8.58M

--0.00

-100.00%0.00

50.02%-204.77K

-100.00%0.00

144.53%29.89K

781091.20%41.47M

-263.79%-409.66K

1488387200.00%14.88M

---67.13K

531000.00%5.31K

1196.54%250.12K

100.00%1.00

--0.00

---1.00

-47.74%-22.81K

-33571.35%-1.41M

-53.70%-15.44K

--4.22K

---10.04K

Net cash flow

Beginning cash balance

146.45%139.22M

4089.72%38.27M

2418.83%77.74M

3020.72%73.44M

516.36%56.49M

-93.85%913.42K

62.01%3.09M

-40.52%2.35M

27.50%9.17M

157.03%14.86M

-94.09%1.91M

-89.19%3.96M

-82.36%7.19M

-87.11%5.78M

-31.22%32.21M

280.98%36.61M

192.04%40.75M

277274.75%44.85M

601525.64%46.84M

73004.84%9.61M

75500.11%13.95M

33.81%16.17K

-58.77%7.79K

-80.68%13.14K

-95.14%18.46K

-98.25%12.08K

--18.88K

--68.03K

2177.57%379.56K

1802.06%690.92K

38.46%16.66K

--36.33K

--12.04K

Current period cash flow changes

-628.86%-89.65M

81.64%100.95M

-1716.49%-39.47M

486.72%4.30M

348.84%16.95M

1075.70%55.58M

-116.77%-2.17M

135.74%733.11K

-110.77%-6.81M

-504.95%-5.70M

149.02%12.96M

53.36%-2.05M

21.91%-3.23M

134.34%1.41M

-1227.75%-26.43M

-111.82%-4.40M

4.72%-4.14M

-129.39%-4.10M

-23845.75%-1.99M

694632.18%37.23M

-81674.89%-4.34M

218559.32%13.94M

223.26%8.38K

89.09%-5.36K

98.29%-5.31K

102.05%6.37K

---6.80K

---49.14K

-742.15%-311.53K

-1483.76%-311.37K

-42.28%48.51K

---19.66K

--84.05K

Ending cash balance

-32.50%49.57M

146.45%139.22M

4089.72%38.27M

2418.83%77.74M

3020.72%73.44M

516.36%56.49M

-93.85%913.42K

62.01%3.09M

-40.52%2.35M

27.50%9.17M

157.03%14.86M

-94.09%1.91M

-89.19%3.96M

-82.36%7.19M

-87.11%5.78M

-31.22%32.21M

280.98%36.61M

192.04%40.75M

277274.75%44.85M

601525.64%46.84M

73004.84%9.61M

75500.11%13.95M

33.81%16.17K

-58.77%7.79K

-80.68%13.14K

104.86%18.46K

--12.08K

--18.88K

4.37%68.03K

-2177.57%-379.56K

-32.17%65.18K

---16.66K

--96.09K

Free cash flow

-164.73%-12.06M

-40.60%-7.52M

-117.02%-10.59M

-10.29%-5.57M

-17.81%-4.56M

-55.28%-5.35M

-18.90%-4.88M

---5.05M

35.25%-3.87M

3.20%-3.44M

28.04%-4.11M

----

---5.97M

---3.56M

---5.70M

---4.40M

----

--1.01M

----

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Inhibikase Therapeutics Inc Generate?



Inhibikase Therapeutics Inc generated -27.79M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Inhibikase Therapeutics Inc's Operating Cash Flow Change Year Over Year?



Inhibikase Therapeutics Inc's operating cash flow increased by -45.11% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Inhibikase Therapeutics Inc Spend on Capital Expenditures?



Inhibikase Therapeutics Inc spent 452.02K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Inhibikase Therapeutics Inc's Financing Cash Flow Changed?



Inhibikase Therapeutics Inc used 108.46M in financing activities in the latest quarter.

What is free cash flow and why does it matter for IKT?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Inhibikase Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -28.24M reflecting a -47.47% change from the previous year.